Akero Therapeutics Inc [AKRO] stock is trading at $54.26, up 0.48%. An important factor to consider is whether the stock is rising or falling in short-term value. The AKRO shares have gain 1.01% over the last week, with a monthly amount glided 16.56%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, TD Cowen started tracking the stock with Buy rating on August 04, 2025, and set its price target to $76. On January 30, 2025, upgrade upgraded it’s rating to Buy and revised its price target to $63 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $72 on January 27, 2025. Citigroup initiated its recommendation with a Buy and recommended $65 as its price target on November 18, 2024. In a note dated September 19, 2023, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $69 on this stock.
Akero Therapeutics Inc [AKRO] stock has fluctuated between $21.34 and $58.40 over the past year. Currently, Wall Street analysts expect the stock to reach $54.67 within the next 12 months. Akero Therapeutics Inc [NASDAQ: AKRO] shares were valued at $54.26 at the most recent close of the market. An investor can expect a potential return of 0.76% based on the average AKRO price forecast.
Analyzing the AKRO fundamentals
Gross Profit Margin for this corporation currently stands at 0.25% with Operating Profit Margin at -80370.75%, Pretax Profit Margin comes in at -70989.75%, and Net Profit Margin reading is -70989.75%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.32 and Total Capital is -0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 54.03 points at the first support level, and at 53.79 for the second support level. However, for the 1st resistance point, the stock is sitting at 54.40, and for the 2nd resistance point, it is at 54.54.
Ratios To Look Out For
For context, Akero Therapeutics Inc’s Current Ratio is 12.66. On the other hand, the Quick Ratio is 12.66, and the Cash Ratio is 3.65.
Transactions by insiders
Recent insider trading involved Cheng Andrew, President and CEO, that happened on Oct 10 ’25 when 30000.0 shares were sold. Chief Scientific Officer, Rolph Timothy completed a deal on Oct 07 ’25 to sell 12500.0 shares. Meanwhile, Officer Timothy Rolph bought 56369.0 shares on Oct 07 ’25.
